Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00384098 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

A Phase 2 study, sponsored by OPKO Health.

Completed
Registry status
Phase 2
Development phase
140
Enrollment target

NCT00384098: Completed Phase 2 study, sponsored by OPKO Health.

NCT00384098 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00384098, a Phase 2 study, has completed, sponsored by OPKO Health.

COMPLETED
Registry status
Phase 2
Development phase
140 participants
Enrollment target

Study Summary

Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one of three doses of CTA018 cream or vehicle (no study drug) daily for 12 weeks.

Interventions

  • DRUG CTA018 cream

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2006-09
Est. Completion 2007-05
Phase Phase 2
OPKO Health

32 total trials

What the finished NCT00384098 record still lists

NCT00384098 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which CTA018 cream is the first listed.

NCT00384098 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00384098 about?

NCT00384098 is a clinical study titled "Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis". Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one...

What is the current status of trial NCT00384098?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2006-09. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00384098?

The interventions under investigation include: CTA018 cream (DRUG).

Who is sponsoring clinical trial NCT00384098?

This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00384098's enrollment target sits among peer trials

140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00384098, the US trial registry maintained by the National Library of Medicine. NCT00384098 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.